Wayne Kuznar
Wayne Kuznar is a contributor to Urology Times.
Low-dose computed tomography found viable in testicular cancer patients
Low-dose computed tomography scans reduce radiation exposure while maintaining diagnostic quality in patients with stage I testicular germ cell tumors being managed with surveillance following orchiectomy.
Titration of renal cell carcinoma treatment may be needed for optimum efficacy
Dose titration of the vascular endothelial growth factor receptor inhibitor axitinib (Inlyta) to achieve therapeutic blood levels may be required for patients with metastatic renal cell carcinoma to derive optimal benefit from the drug as second-line therapy.
5-alpha-reductase inhibitors not efficacious for secondary prevention of prostate cancer
Observational data fail to support a role of 5-alpha-reductase inhibitors (5-ARIs) for secondary prevention of clinically significant prostate cancer in men with very low-risk disease.
Clinical trial ineligibility tied to poor renal cell carcinoma outcomes
The number of patients with metastatic renal cell carcinoma (mRCC) who are ineligible for clinical trials is high, and their clinical outcomes are inferior to those who are trial eligible.
External beam radiation therapy more costly than brachytherapy, prostatectomy
A retrospective long-term comparison of three prostate cancer treatment strategies revealed that treatment with external beam radiation therapy (EBRT) resulted in more long-term toxicities and higher treatment-related costs than prostatectomy and brachytherapy.
Radiation analysis bolsters intensity-modulated radiation therapy as current standard
A comparative effectiveness analysis of three techniques for delivering radiation therapy for the treatment of localized prostate cancer supports intensity-modulated radiation therapy (IMRT) as the current standard.
Prostate cancer agent increases bone metastasis-free survival
PSA kinetics can be used to identify patients with nonmetastatic castration-resistant prostate cancer (CRPC) who are at enhanced risk for bone metastases or death.
Clinical pathway allows for discharge of nephrectomy patients on post-op day 1
Applying a clinical pathway to patients undergoing robotic partial nephrectomy can take advantage of the minimally invasive procedure and permit discharge on postoperative day 1 in most cases.
Denosumab results in less pain interference, according to study
Pain interference with daily functioning was significantly less in men with castrate-resistant prostate cancer who were treated with the RANK ligand inhibitor denosumab (XGEVA) compared to zoledronic acid (Zometa) as part of a multinational, double-blind, randomized trial.
Prostate cancer screening should monitor subgroup of young, high-risk men, study suggests
Almost half of prostate cancer deaths occur among men with PSA levels in the top 10% when assessed at age 44 to 50 years. This small group could benefit from intense surveillance over the ensuing years, whereas in about half of men, three lifetime PSA tests appear sufficient to capture the risk of prostate cancer metastases or death 10 or more years in advance.


View Results